Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

20d ago UK CMA Publications
Favicon for www.gov.uk

CMA Advocates Non-Compete Clause Reform and Salary Threshold Ban

The UK's Competition and Markets Authority (CMA) has responded to a government working paper on reforming non-compete clauses in employment contracts. The CMA advocates for reforms, including a ban on non-competes below a salary threshold, to enhance labour market mobility.

Priority review Guidance Employment & Labor
Favicon for www.fca.org.uk

FCA Stablecoin Regulatory Sandbox Testing

The FCA has selected four firms to participate in its regulatory sandbox to test stablecoin innovation. This initiative aims to gather real-world data to inform the development of future UK stablecoin regulations, with findings expected to shape final rules later in 2026.

Priority review Guidance Securities
Favicon for www.fca.org.uk

Payments Forward Plan Published by Committee

The Payments Vision Delivery Committee, comprising HM Treasury, Bank of England, FCA, and PSR, has published the Payments Forward Plan. This plan outlines upcoming initiatives in retail and wholesale payments, including digital assets, to foster innovation and economic growth.

Priority review Guidance Payments
20d ago UK CMA Cases
Favicon for www.gov.uk

CMA Investigates ABF Acquisition of Hovis Merger

The UK's Competition and Markets Authority (CMA) has launched an investigation into the anticipated acquisition of Hovis Group Limited by Associated British Foods plc. The inquiry is currently in Phase 2, with a statutory deadline of June 24, 2026.

Priority review Enforcement Antitrust & Competition
20d ago UK CMA Cases
Favicon for www.gov.uk

CMA Investigates Hays Travel Merger

The UK's Competition and Markets Authority (CMA) has launched merger inquiries into Hays Travel's acquisitions of Polka Dot Travel and Millington Travel. Initial enforcement orders have been served, and phase 1 decision deadlines are set for April 2026.

Priority review Enforcement Antitrust & Competition
20d ago UK CMA Cases
Favicon for www.gov.uk

Homes England Subsidy Referral for 2020 Developments Luton

The UK's Competition and Markets Authority (CMA) has published its final report advising Homes England on a proposed £29.5 million subsidy to 2020 Developments (Luton) Limited. This subsidy is for infrastructure development to unlock residential and employment space.

Priority review Guidance International Trade
20d ago UK CMA Cases
Favicon for www.gov.uk

CMA Merger Inquiry: LDC acquires Green Label

The CMA has opened a merger inquiry into the acquisition of Green Label Holdings Limited by Société LDC SA. An initial enforcement order has been served, and an invitation to comment is open until March 9, 2026, to gather views on potential competition impacts.

Priority review Consultation Antitrust & Competition
20d ago UK CMA Cases
Favicon for www.gov.uk

Post Office Subsidy Scheme Report and Consultation

The CMA's Subsidy Advice Unit has accepted a request for a report on the proposed £609.2m Post Office Transformation Subsidy Scheme. The Department for Business and Trade is seeking advice on compliance with subsidy control requirements. Comments are due by March 11, 2026.

Priority review Consultation International Trade
20d ago EMA News
Favicon for www.ema.europa.eu

EMA Recommends Six New Medicines for Approval

The European Medicines Agency's CHMP has recommended six new medicines for marketing authorisation and nine for extension of therapeutic indications. These recommendations cover treatments for various conditions including menopausal symptoms, liver disease, a rare genetic disorder, influenza, and graft-versus-host disease.

Priority review Notice Pharmaceuticals
20d ago EMA News
Favicon for www.ema.europa.eu

EMA Recommends Kygevvi for Rare TK2d Disease Treatment

The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Kygevvi, a new treatment for the rare genetic disease thymidine kinase 2 deficiency (TK2d). This recommendation is based on clinical study data showing improvement in motor function for pediatric patients.

Priority review Guidance Pharmaceuticals

Showing 13001–13010 of 14,423 changes

1 1299 1300 1301 1302 1303 1443

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.